Zepbound and Mounjaro activate brown fat in obese rats

Tirzepatide, marketed under the names Mounjaro and Zepbound, has shown the ability to activate brown fat—which is responsible for calorie burning—in obese rats.

The finding indicates that the medication may exert an additional metabolic effect alongside its well-known appetite-reducing properties. If the same mechanism is confirmed in humans, it could help explain the robust benefits observed with the use of tirzepatide.

In addition to expanding the understanding of how the drug works, the discovery opens up possibilities for developing more comprehensive approaches to treating obesity and diabetes.

With information from ScienceDaily.